# Safety and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study

> **NCT01772251** · PHASE1,PHASE2 · COMPLETED · sponsor: **Oshadi Drug Administration** · enrollment: 10 (actual)

## Conditions studied

- Diabetes Mellitus, Insulin-Dependent, 1

## Interventions

- **DRUG:** Oshadi Icp

## Key facts

- **NCT ID:** NCT01772251
- **Lead sponsor:** Oshadi Drug Administration
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2013-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01772251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01772251, "Safety and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01772251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*